In prostate cancer, TMPRSS2 gene alterations serve as important biomarkers, with TMPRSS2-ETS gene fusions (particularly TMPRSS2-ERG) occurring in approximately 50% of cases and associated with aggressive disease features [8,9,10,11,12,13,14,15]. Here, TMPRSS2 is linked to prostate carcinoma.